Lung Cancer

FDA Clears Pancreatic Drug That Shows Early Promise in RAS‑Mutant Lung Cancer

The drug’s cyclophilin A 'molecular glue' mechanism targets a broad set of RAS mutations, with an ongoing Phase 3 trial set to decide a lung‑cancer approval.